Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on... see more

CSE:QNTM - Post Discussion

Quantum BioPharma Ltd > To achieve Change
View:
Post by junjun26 on Apr 02, 2021 2:33pm

To achieve Change

One way to achieve CHANGE is that by implementing a strong financial and corporate governance framework so that directors and management are restricted in granting compensation to themselves at levels higher than industry standards.

Comment by junjun26 on Apr 02, 2021 2:35pm
Indeed a Good action! The  Board  (other  than Concerned  Shareholders)  have  enabled Dr.  Bokhari despite  his  poor  performance  and have disregarded his misconduct, including threatening two of the Concerned Shareholders and taking actions that have gratuitously exposed the Company to legal actions. 
Comment by junjun26 on Apr 02, 2021 2:36pm
The  Concerned  Shareholders  have  taken  action, both  by  requisitioning  a  special  meeting  and  later  by  Court action at their personal cost, to compel the Company to hold the Meeting in a timely fashion in order to address the continued erosion of Shareholder value as soon as possible.
Comment by junjun26 on Apr 02, 2021 2:37pm
In  the  face  of  these  challenges,  and  with  clear  disregard  to  the  interests of  Shareholders,  the  Board  has aggressively issued an extraordinary number of Shares in just seven weeks –equal too ver 83% of the number outstanding on January 4, 2021.
Comment by junjun26 on Apr 02, 2021 2:37pm
So the Company’s future will be implementing audits of prior compensation and expenses incurred by the Company; and developing  a  robust  investor  relations  function  to better  communicate  FSD’s  value  to  the  investment community. 
Comment by junjun26 on Apr 02, 2021 2:54pm
If elected at the upcoming shareholder meeting on May 14, 2021, the nominees hope to restore FSD .
Comment by junjun26 on Apr 02, 2021 2:55pm
To restore they will acquire biotechnology assets focused on legal medical cannabis and/or legal psychedelics to increase the Company’s drug development pipeline and reduce reliance on a single compound;
Comment by junjun26 on Apr 02, 2021 2:56pm
Auditing the Company’s current Phase 2 clinical trial to determine its current viability and better understand the risks and costs so that appropriate budgets can be created and followed and to determine whether it should be continued. Right
Comment by Boni94 on Apr 02, 2021 3:00pm
Yes there are many things to consider and needs to to achieve if ever there is a new CEO appointed after voting.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities